In a nutshell
This study looked at the effectiveness of adding inotuzumab ozogamicin (Besponsa) and blinatumomab (Blincyto) to low-intensity chemotherapy in the treatment of ALL. Researchers found that this combination of treatment was effective in these patients.
Some background
Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow. This leads to abnormal cells in the immune system. It is often treated with medications that target the immune cells. Some patients experience relapse after first-line treatments. New drug combinations are being developed. It is important to research the safety and effectiveness of these treatments in patients with relapsed ALL.
Methods & findings
48 patients with relapsed ALL were treated with low-intensity chemotherapy. This included cyclophosphamide (Cytoxan), vincristine (Oncovin), and dexamethasone (Decadron). Inotuzumab ozogamicin was given on day 3 of each treatment. Blinatumomab was given for 4 cycles of treatment after inotuzumab. Patients were followed up for an average of 31 months.
Overall, 44 (92%) patients responded to the new treatment plan. 35 (73%) had no signs of cancer after treatment (complete response). 24 (50%) patients had a stem cell transplant after treatment. Of these, 14 were still alive at followed-up. Of the 20 patients who did not get a stem cell transplant after treatment, 6 (30%) had no signs of cancer after the last follow-up.
42% of patients were alive without cancer growing at 2 years. Overall survival rate at 2 years was 54%. Most side effects were mild. Blood vessel blockage was reported in 10% of patients.
The bottom line
The study concluded that adding inotuzumab ozogamicin and blinatumomab to chemotherapy was safe and effective in the treatment of relapsed ALL.
The fine print
This study is limited by a small sample size. Larger studies are needed to confirm results.
What’s next?
Talk to your doctor about different treatment plans for ALL.
Published By :
Cancer
Date :
Oct 11, 2018
